Foundation News

Stay up-to-date with the most current news and information about the Crohn's & Colitis Foundation, as well as Crohn's disease and ulcerative colitis.

Child With Ibd

Foundation Receives $1 Million Donation from the Wilbur May Foundation to Advance Pediatric IBD Research and Programs

The Crohn’s & Colitis Foundation has received a $1 million donation from the Wilbur May Foundation, an organization dedicated to the welfare of youth in the greater San Diego region and nationwide.

January 30, 2024

UC

Crohn’s & Colitis Foundation and Evotec Enter Agreement to Advance Drug Discovery for Novel IBD Therapies

he Crohn’s & Colitis Foundation has joined forces with life science company Evotec SE, to help advance drug discovery for two innovative drug targets stemming from cutting-edge academic research for inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis.

January 9, 2024

Foundation Funded Research, Published in Nature, Finds Biomarker for Inflammatory Bowel Disease

In recent years, microbiome research has started to shift it

December 6, 2023

The Crohn’s & Colitis Foundation Appoints Christy DeSantis as Chief Marketing & Communications Officer

Christy DeSantis, an accomplished marketing executive, begins her tenure today as the Chief Marketing & Communications Officer at the Crohn’s & Colitis Foundation. Tasked with steering the Foundation’s marketing and communications strategies, DeSantis joins the senior leadership team, playing a crucial role in shaping impactful initiatives across the organization.

October 30, 2023

Mark Cuban Cost Plus Drugs

The Crohn’s & Colitis Foundation Joins Forces with the Mark Cuban Cost Plus Drug Company to Improve Medication Access for IBD Patients

The Crohn’s & Colitis Foundation, the nation’s leading nonprofit organization focused on research and patient support for inflammatory bowel disease (IBD), is joining forces with the Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) to increase awareness of opportunities for accessing some reduced-price essential IBD medications.  

October 3, 2023

Alan Moss

The Crohn’s & Colitis Foundation Appoints Alan Moss, MD, as Chief Scientific Officer

Alan Moss, MD, a renowned clinician-scientist, begins his tenure today as the Chief Scientific Officer at the Crohn’s & Colitis Foundation. His prior roles include serving as the Director of the Crohn’s & Colitis Program at Boston Medical Center (BMC) and Professor of Medicine at Boston University (BU). In his clinical practice, Dr. Moss has cared for IBD patients from underserved, immigrant, and unhoused populations.

September 25, 2023